1181: Bicalutamide 150 MG in Addition to Standard Care in Patients With Early, Non-Metastatic Prostate Cancer: Results from the SPCG-6 Study at a Median Follow-up of 5.3 Years

Prostate cancer is the most common malignancy in men. The 5-year relative survival for all stages combined is 98.8%. Patients diagnosed with metastatic prostate cancer have median survival from 2 to 3 years. We describe a case of 64-year old man who clinically presented with inguinal lymphadenopathy. Because of elevated PSA levels biopsy of prostate was done and adenocarcinoma was diagnosed. Biopsy of inguinal lymph nodes confirmed the diagnosis of prostate cancer. Hormonal treatment was started and at the most recent follow-up, 10 years later, the patient is asymptomatic with no clinical signs of disseminated disease.

Download Full-text

Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.7_suppl.140 ◽

2015 ◽

Vol 33 (7_suppl) ◽

pp. 140-140 ◽

Cited By ~ 14

Author(s):

Gwenaelle Gravis ◽

Jean-Marie Boher ◽

Florence Joly ◽

Stephane Oudard ◽

Laurence Albiges ◽

...

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

High Volume ◽

Phase Iii ◽

Phase Iii Trial ◽

Intention To Treat ◽

Original Analysis ◽

Definition Of

140 Background: ADT is standard treatment for metastatic PCa. Recently, the E3805 trial reported a survival benefit for (ADT+D) in high volume disease (HVD) patients, whereas the GETUG-15 trial did not demonstrate a survival improvement among a less selected group of patients (pts) with hormone-naïve metastatic PCa. We report an updated analysis of overall survival (OS) of the GETUG 15 trial and aligned the definition of HVD and low volume disease (LVD) subgroups. Methods: Long-termOS was analyzed in the intention-to-treat population (n=385 pts). Additionally, we retrospectively assessed the tumor volume as defined per E3805criteria in all patients enrolled in GETUG 15. Results: See Table. With a median follow-up of 82.9 months (95%CI [80.5-84.3]) (vs 50 months (95%CI [80.5-84.3] in the original analysis), 212 patients (55%) have died. The median OS is 46.5 [39.1-60.6] and 60.9 months [46.1-71.4] in the ADT and in the ADT + D arms, respectively (HR: 0.9 [95%CI: 0.7-1.2]). In HVD patients (n=183, 47.5%), median OS rates were 35.1 months [29.9-44.2] in the ADT alone arm and 39 months [28-52.6] in the ADT+D arm (HR: 0.8 [0.6-1.2]). Conclusions: With longer follow-up, the addition of docetaxel to ADT did not significantly improve OS in patients with hormone-naïve metastatic prostate cancer. In the retrospective analysis using aligned definition of volume of metastasis as E3805, the HVD outcomes were similar to E3805 for ADT alone and there was a non-significant 4 months increase in OS with ADT+D, in this underpowered subset. Clinical trial information: 00104715. [Table: see text]

Download Full-text

Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.

Canadian Urological Association Journal ◽

10.5489/cuaj.175 ◽

2013 ◽

Vol 7 (7-8) ◽

pp. 544 ◽

Cited By ~ 36

Author(s):

Rafal Turo ◽

Samer Jallad ◽

William Richard Cross ◽

Stephen Prescott

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Estrogen Therapy ◽

Hormone Ablation ◽

Castrate Resistant ◽

Male To Female

The incidence of prostate cancer in transsexual patients is very low with only few reported cases. Many years before presenting with prostate cancer, these patients receive hormone ablation as a part of their gender therapy. Their disease is already defined as castrate resistant, and the treatment and follow-up of such patients remains a challenge. We report a case of a male-to-female transgender woman who was diagnosed with metastatic prostate cancer, 31 years post-feminization.

Download Full-text